[EN] DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] PRODUITS THÉRAPEUTIQUES DÉRIVÉS D'ÉTHERS DIGLYCIDIQUES ET LEURS PROCÉDÉS D'UTILISATION
申请人:BRITISH COLUMBIA CANCER AGENCY
公开号:WO2010000066A1
公开(公告)日:2010-01-07
This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Compounds having a structure of Formula I: wherein G, a, Q, L
2
, R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
[EN] BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS DE BISPHÉNOL ET LEURS PROCÉDÉS D'UTILISATION
申请人:BRITISH COLUMBIA CANCER AGENCY
公开号:WO2012139039A3
公开(公告)日:2013-04-25
US9173939B2
申请人:——
公开号:US9173939B2
公开(公告)日:2015-11-03
[EN] BISPHENOL A COMPOUNDS AND METHODS FOR TREATING DRUG-RESISTANT ANDROGEN RECEPTOR MEDIATED CANCERS<br/>[FR] COMPOSÉS DE BISPHÉNOL A, ET MÉTHODES DE TRAITEMENT DE CANCERS POSITIFS POUR LE RÉCEPTEUR AUX ANDROGÈNES RÉSISTANTS AUX MÉDICAMENTS
申请人:BRITISH COLUMBIA CANCER AGENCY BRANCH
公开号:WO2018045450A1
公开(公告)日:2018-03-15
The present invention provides methods for treating cancer comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein the cancer, cancer cells, or tumour cells are resistant to a cancer agent which is susceptible to glucuronidation. R1, R2, R3, R11a, R11b, R11c, and R11d are as defined herein. (Formula (I))